DarioHealth Presents Dario Engage Vision at the HIMSS Annual Conference & Exhibition

    DarioHealth Goes to Las Vegas to Share Vision on Shifting Diabetes Monitoring to a Focus on Personalization

    Mar 5, 2018

    LAS VEGAS, Mar 5, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced it is sharing its Dario Engage vision of moving diabetes management to focus on personalization this week at the HIMSS (Healthcare Information and Management Systems Society) Annual Conference & Exhibition (Booth #10343).


    DarioHealth's vision includes going from the traditional approach, which bases itself on general statistics-based management, to a smart approach that is based on continuous accumulation of data that assists in better care. Dario Engage is expected to be a preeminent platform that is data and performance driven, which will support diabetes coaching services on a larger scale.

    Erez Raphael, Chairman and CEO of DarioHealth, commented, "HIMSS18 is the foremost event in our industry and a great stage to showcase Dario Engage, which is our next step in the DarioHealth story. By combining a compact, accurate all-in-one device with digital engagement for diabetes data management, we have achieved critical success in the direct-to-consumer market. Now, we're taking our learnings to the next level and offering it as a management tool to hospitals and clinics to better manage their patients with the goal of achieving improved clinical outcomes."

    HIMSS is a nonprofit organization whose goal is to promote the best use of information technology and management systems in the health care industry. The organization's HIMSS Annual Conference & Exhibition is taking place this week, March 5-9, 2018 at the Venetian-Palazzo Sands Expo Center in Las Vegas. It is one of the health information and technology industry's leading conferences and is expected to attract over 40,000 health IT professionals, clinicians, executives and vendors from around the world.

    For more information about Dario Engage, speak to the DarioHealth team at the Israel Export Institute booth #10343 or visit http://www.dariohealth.com/solutions/dario-engage/

    About DarioHealth Corp.

    DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today's day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease data management, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel. For more information, visit http://mydario.investorroom.com/.

    Cautionary Note Regarding Forward-Looking Statements

    This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company describes the vision and benefits of Dario Engage, and that Dario Engage is expected to be a preeminent platform that is data and performance driven which will support diabetes coaching services on a larger scale, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

    DarioHealth Corporate Contact: Shmuel Herschberg, Marketing Director, shmuel@mydario.com, +1-914-775-5548

    DarioHealth Public Relations Contact: Terese Kelly, Rosica PR, terese@rosica.com, +1-201-843-5600

    DarioHealth Investor Relations Contact: Westwicke Partners, Dario@Westwicke.com, +1-443-213-0500

    SOURCE DarioHealth Corp.

    print email rss